Monday June 26th 2017

Archive for July, 2010

MS procedure raises hope

MS procedure raises hope

Using a walker, Dawn Grainger makes her way to the front doors of The Expositor building on Dalhousie Street. Full of determination, bright as ever and fully engaged in life, Grainger, the former executive director of the Brant United Way, flashes a wide smile. [Read More]

MS relief sought in Costa Rica

MS relief sought in Costa Rica

On Sunday, 24-year-old Lilly Cadeau will be boarding a plane bound for Costa Rica. For most people her age, the Central American country holds promise of an exciting backpacking trip, or a pleasant, relaxing vacation on one of its many sandy beaches. But for Cadeau, Costa [Read More]

B.C. urged to join MS trials

B.C. urged to join MS trials

B.C. should take Saskatchewan up on its invitation to help fund clinical trials of a controversial new treatment for multiple sclerosis, a provincial New Democrat says. “There’s urgency here,” said NDP legislative member Adrian Dix, the B.C. opposition [Read More]

 Page 1 of 14  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]